Skip to main content

Table 2 Primary and secondary outcomes

From: Early combination of albumin with crystalloids administration might be beneficial for the survival of septic patients: a retrospective analysis from MIMIC-IV database

Outcomes Crystalloids (n = 6597) Combination (n = 920) Difference
(95%CI)
P
Values 95%CI Values 95%CI
Before PSM
 RMST for 28 days (days) 23.37 23.12–23.61 25.10 24.6–25.6 1.73 (1.17–2.29)  < 0.001
 RMST for 60 days (days) 46.09 45.31–46.88 50.93 49.37–52.49 4.84 (3.09–6.58)  < 0.001
 LOS ICU (days) 6.65 6.47–6.83 10.37 9.65–11.09 3.72 (2.98–4.46)  < 0.001
 LOS Hospital (days) 14.32 13.93–14.71 19.03 18.00–20.07 4.72 (3.61–5.82)  < 0.001
 Total volume of crystalloids (L) 2.37 2.27–2.41 3.11 2.84–3.40 0.78 (0.49–1.07)  < 0.001
After PSM (1:1)
 RMST for 28 days (days) 22.20 21.53–22.86 25.10 24.60–25.60 3.23 (2.38–4.08)  < 0.001
 RMST for 60 days (days) 42.18 40.09–44.27 50.93 49.37–52.49 9.09 (6.49–11.69)  < 0.001
 LOS ICU (days) 7.73 7.25–8.21 10.37 9.65–11.08 2.64 (1.77–3.50)  < 0.001
 LOS Hospital (days) 15.21 14.89–17.44 19.04 18.00–20.07 2.88 (1.24–4.52)  < 0.001
 Total volume of crystalloids (L) 2.76 2.46–3.06 3.11 2.84–3.40 0.36 (-0.05–0.77) 0.085
  1. RMST (days) means the restricted mean survival time in each group during the first 28 and 60 days after ICU admission. The difference in RMST (95%CI) was calculated with the difference of restricted mean survival time between the two groups (RMSTcombination-RMSTcrystalloids), which means the increment or reduction of survival owing to the combination therapy. LOS ICU Length of ICU stay, LOS Hospital Length of hospital stay, PSM propensity score matching
\